Clinical commissioning policy: Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease

Document first published:: 6 November 2023
Page updated:: 6 November 2023
Topic:: Specialised commissioning
Publication type:: Policy or strategy

Subcutaneous copper histidinate is recommended to be available as a routine commissioning treatment option for presymptomatic neonates with classical Menkes disease within the criteria set out in this document.

Document

Clinical Commissioning Policy: Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease

Clinical Commissioning Policy: Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease

PDF
279 KB
9 pages

Document

Clinical panel report: Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease

Clinical panel report: Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease

PDF
132 KB
3 pages

Document

Clinical priorities advisory group report: Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease

Clinical priorities advisory group report: Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease

PDF
166 KB
12 pages

Document

Equality and Health Inequalities Impact Assessment (EHIA): Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease

Equality and Health Inequalities Impact Assessment (EHIA): Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease

PDF
78 KB
10 pages

Document

Evidence review: Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease

Evidence review: Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease

PDF
450 KB
46 pages